Trial NCT03745222

View at ClinicalTrials.gov 
Org. Study IDs: BGB-A317-NSCL-001
Secondary IDs: 2018-001132-22 U1111-1216-4294

Last trial update was posted on 2020-07-15

MeSH Interventions

Tislelizumab

MeSH Conditions

Carcinoma, Non-Small-Cell Lung Lung Neoplasms

Other Conditions


Stopping Reasons

BeiGene and Celgene Corporation terminated the parties' global collaboration for the compound, pending the acquisition of Celgene by Bristol Myers Squibb

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID